Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sangamo Therapeutics (SGMO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 1,212,345
  • Shares Outstanding, K 83,610
  • Annual Sales, $ 19,390 K
  • Annual Income, $ -71,660 K
  • 36-Month Beta 3.14
  • Price/Sales 64.04
  • Price/Cash Flow 0.00
  • Price/Book 5.51

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.80 +10.55%
on 09/26/17
17.06 -17.03%
on 10/05/17
-0.60 (-4.07%)
since 09/18/17
3-Month
8.00 +76.87%
on 08/01/17
17.06 -17.03%
on 10/05/17
+4.90 (+52.97%)
since 07/18/17
52-Week
2.65 +433.96%
on 12/08/16
17.06 -17.03%
on 10/05/17
+10.25 (+262.82%)
since 10/18/16

Most Recent Stories

More News
Sangamo Therapeutics Announces Presentations At 2017 Annual Congress Of The European Society Of Gene And Cell Therapy

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today presentations by Company scientists at the 2017 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT). The meeting is being...

SGMO : 14.15 (-2.41%)
Best Sector ETF of Q3 and its Top-Performing Stocks

Inside the top performing stocks of top U.S.-focused ETF of Q3.

SGMO : 14.15 (-2.41%)
BBC : 28.55 (-0.80%)
DVAX : 20.40 (-3.66%)
KITE : 179.99 (+0.11%)
MYOK : 36.60 (-1.35%)
INSM : 27.82 (-0.68%)
Sangamo And Bioverativ Announce FDA Acceptance Of IND Application For ST-400 -- A Gene-Edited Cell Therapy Candidate -- To Treat Beta-Thalassemia

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, and Bioverativ Inc. (NASDAQ: BIVV), a global biopharmaceutical company focused on the discovery, development, and commercialization...

SGMO : 14.15 (-2.41%)
BIVV : 59.96 (-0.18%)
Best Sector ETF of Q3 and its Top-Performing Stocks

Inside the top performing stocks of top U.S.-focused ETF of Q3.

SGMO : 14.15 (-2.41%)
BBC : 28.55 (-0.80%)
DVAX : 20.40 (-3.66%)
KITE : 179.99 (+0.11%)
MYOK : 36.60 (-1.35%)
INSM : 27.82 (-0.68%)
Sangamo Therapeutics Announces Participation At Upcoming Investor And Industry Conferences

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's chief executive officer, will participate in the following conferences in October.

SGMO : 14.15 (-2.41%)
Sangamo Therapeutics Announces Presentation At The 2017 Cantor Fitzgerald Global Healthcare Conference

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's chief executive officer, will present at the 2017 Cantor Fitzgerald Global Healthcare Conference...

SGMO : 14.15 (-2.41%)
4 Biotech Stocks That Show Promise on Sustainable Growth

Biotech sector is performing well in 2017 due to an increase in FDA approvals, new product sales ramp up, R&D success and innovation, strong clinical study results and continued strong performance of legacy...

SGMO : 14.15 (-2.41%)
HSKA : 96.39 (-0.09%)
CORT : 18.47 (+0.98%)
LLY : 85.73 (-0.38%)
HLUYY : 60.7700 (-0.96%)
GILD : 80.01 (-0.29%)
KITE : 179.99 (+0.11%)
ALXN : 140.24 (-2.04%)
The Zacks Analyst Blog Highlights: Caladrius Biosciences, Orexigen Therapeutics, Sangamo Therapeutics and Syndax Pharmaceuticals

The Zacks Analyst Blog Highlights: Caladrius Biosciences, Orexigen Therapeutics, Sangamo Therapeutics and Syndax Pharmaceuticals

SGMO : 14.15 (-2.41%)
OREX : 1.87 (-1.06%)
CLBS : 3.39 (-4.24%)
SNDX : 12.05 (-0.90%)
Why These 4 Biotech Stocks May Not Lose Momentum Soon

The biotech industry has shown strength so far this year. The momentum is likely to continue for some time, it's a good idea to pick a few stocks that are unlikely to lose their momentum soon.

SGMO : 14.15 (-2.41%)
OREX : 1.87 (-1.06%)
CLBS : 3.39 (-4.24%)
SNDX : 12.05 (-0.90%)
5 Top-Ranked Biotech Stocks to Buy Right Now

If you are looking to invest in the biotech sector, here is a peek at 5 buy-ranked biotech stocks including Regeneron Pharmaceuticals (REGN).

SGMO : 14.15 (-2.41%)
LGND : 144.16 (+1.41%)
GILD : 80.01 (-0.29%)
REGN : 439.37 (-0.72%)
KITE : 179.99 (+0.11%)
FATE : 4.17 (+2.21%)
ALXN : 140.24 (-2.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc.,...

See More

Support & Resistance

2nd Resistance Point 15.15
1st Resistance Point 14.65
Last Price 14.15
1st Support Level 13.80
2nd Support Level 13.45

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart